Short answer
Quest Diagnostics (DGX) filed an 8-K current report with the SEC on October 6, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Catherine Doherty retirement planned for July 2027, creating a future senior leadership transition.
Quest Diagnostics 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Catherine Doherty retirement planned for July 2027, creating a future senior leadership transition
- Executive Vice President role effective November 1, 2026, retaining oversight of health systems, Corewell Health joint venture and Project Nova
- Base salary unchanged at $650,000, with target annual incentive equal to 80% of base salary
- $1.2 million restricted stock unit award, granted November 3, 2026, supporting retention through transition
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Quest Diagnostics 8-K filings
Get the next DGX 8-K as it lands
Follow DGX for push alerts, or ask the research agent what this filing means.